Immunocore Holdings (IMCR) Receivables (2019 - 2026)

Immunocore Holdings has disclosed Receivables across 8 years of filings, most recently posting $81.1 million for Q1 2026.

• Receivables for Q1 2026 came in at $81.1 million, up 28.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.1 million (up 28.48% YoY), and the FY2025 annual result was $74.0 million, up 17.41% from the prior year.
• Receivables came in at $81.1 million for Q1 2026 at Immunocore Holdings, up from $74.0 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $81.1 million in Q1 2026 to a low of $52.1 million in Q4 2023.
• The 5-year median for Receivables is $63.7 million (2024), against an average of $65.9 million.
• Across the five-year window, Receivables soared 529.62% in 2022 and retreated 18.35% in 2023, its largest moves.
• Immunocore Holdings' Receivables stood at $63.8 million in 2022, then declined by 18.35% to $52.1 million in 2023, then rose by 20.95% to $63.0 million in 2024, then climbed by 17.41% to $74.0 million in 2025, then advanced by 9.59% to $81.1 million in 2026.
• The last three Receivables figures came in at $81.1 million (Q1 2026), $74.0 million (Q4 2025), and $75.9 million (Q3 2025), per Business Quant data.